SAN DIEGO, April 3, 2018 /PRNewswire/ -- OncoSec
Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing
intratumoral cancer immunotherapies, today announced it will host a
Research Reception at the 2018 American Association of Cancer
Research (AACR) Annual Meeting. The reception, for which
registration is required, will be held on Sunday, April 15, 2018 at 6:00 p.m. CT at the JW Marriott in Chicago, IL.
The OncoSec Research Reception will feature the following
presentations:
- OMS-140 Protocol; Review of Intratumoral IL-12 Data in TNBC
Presented at AACR
-
- Pamela Munster, MD, UCSF Helen Diller Family
Comprehensive Cancer Center
- OMS-141 Protocol; Upcoming PD-1 Combination Clinical Trial in
TNBC
-
- Melinda Telli, MD, Stanford University Medical Center
- Melanoma Data Update: OMS-100 & OMS-102 Combination
Study
-
- Alain Algazi, MD, UCSF Helen
Diller Family Comprehensive Cancer Center
- PISCES/KEYNOTE-695 Operational Update
-
- Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer,
OncoSec
Attendees will also have the opportunity to view the TNBC data
featured as an oral poster at AACR and ask questions of the lead
author. All speakers will be available for questions. Space is
limited. For those interested in attending this event in person,
please contact events@oncosec.com.
An archived version of the presentation will be available for 90
days on OncoSec's website: www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-research-reception-during-the-2018-american-association-of-cancer-research-annual-meeting-300623187.html
SOURCE OncoSec Medical Incorporated